This part is a second-generation chimeric antigen receptor, whose scFV segment is derived from trastuzumab. Therefore, this part can target EGFR。
A scFv derevied from Herceptin
This parts contains an scFv derived from the famous antibody trastuzumab, which sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.Therefore the above description is wrong, it can target HER2.
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines. A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.
Sequence and Features
- 10COMPATIBLE WITH RFC
- 12Illegal NotI site found at 971
Illegal NotI site found at 1208
- 21COMPATIBLE WITH RFC
- 23COMPATIBLE WITH RFC
- 25Illegal NgoMIV site found at 847
Illegal NgoMIV site found at 916
- 1000COMPATIBLE WITH RFC